Understanding how certain cancer cells maintain their telomeres
Phase separation-induced nuclear organization in ALT Cancer
['FUNDING_U01'] · CARNEGIE-MELLON UNIVERSITY · NIH-10927228
This study is looking at a special kind of cancer cell that grows differently than usual, and by understanding how these cells work, researchers hope to find new treatments that can help patients while being kinder to healthy cells.
Quick facts
| Phase | ['FUNDING_U01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | CARNEGIE-MELLON UNIVERSITY (nih funded) |
| Locations | 1 site (PITTSBURGH, UNITED STATES) |
| Trial ID | NIH-10927228 on ClinicalTrials.gov |
What this research studies
This research investigates a specific type of cancer cell that does not use the typical method to maintain telomere length, which is crucial for cell immortality. Instead, these cells utilize an alternative method known as the ALT pathway, leading to unique nuclear structures that can be targeted for treatment. By studying how these structures form and function, the research aims to develop new therapeutic strategies that specifically affect cancer cells while sparing healthy ones. Patients may benefit from insights that could lead to more effective and less harmful cancer treatments.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with ALT cancers, particularly those who are telomerase-negative.
Not a fit: Patients with cancers that do not utilize the ALT pathway or those who are telomerase-positive may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to targeted therapies that improve treatment outcomes for patients with ALT cancers.
How similar studies have performed: Previous research has shown promise in targeting unique cancer cell features, suggesting that this approach could yield significant advancements in cancer treatment.
Where this research is happening
PITTSBURGH, UNITED STATES
- CARNEGIE-MELLON UNIVERSITY — PITTSBURGH, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: ZHANG, HUAIYING — CARNEGIE-MELLON UNIVERSITY
- Study coordinator: ZHANG, HUAIYING
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Cancer Cell Growth, Cancer Treatment, Cancers